Weekly Clinical Updates

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19 | Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors | Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study | Variant Influenza Virus Infections: Recommendations for Identification, Treatment, and Prevention for Summer and Fall 2022 | Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals

Clinical Manifestations of Infection with Poliomyelitis Virus | Spike Protein-independent Attenuation of SARS-CoV-2 Omicron Variant in Laboratory Mice | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study | Distinguishing features of Long COVID identified through immune profiling | Unexplained post-acute infection syndromes | Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children

Clinical assessment of confirmed human monkeypox virus cases in Spain | Monkeypox Virus Infection across 16 Countries | Clinical characteristics of ambulatory and hospitalized patients with monkeypox | Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection | Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years | Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age | Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater | Human-to-human transmission of monkeypox virus | What to Do If You Were Exposed to COVID-19 and its Isolation and Precautions for People with COVID-19 | Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations | Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment

Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 | Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 | Profiling post-COVID syndrome across different variants of SARS-CoV-2 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects | Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir

Viral and Symptom Rebound in Untreated COVID-19 Infection | Cognitive Impairment 13 Months After Hospitalization for COVID-19 | Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients | Extended Remdesivir Infusion for Persistent COVID-19 Infection | Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial and updated meta-analysis